ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.251-2A>T

gnomAD frequency: 0.00001  dbSNP: rs587779340
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 18
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000162757 SCV000213233 pathogenic Hereditary cancer-predisposing syndrome 2022-01-28 criteria provided, single submitter clinical testing The c.251-2A>T intronic pathogenic mutation results from an A to T substitution two nucleotides before coding exon 4 in the PMS2 gene. This alteration was identified in a cohort of 1260 individuals undergoing panel testing for Lynch syndrome due to having a diagnosis of a Lynch-associated cancer and/or polyps (Yurgelun MB et al. Gastroenterology. 2015 Sep;149:604-13.e20). This alteration has also been identified in an individual diagnosed with colorectal cancer at 54. Immunohistochemistry of the tumor showed loss of expression of MSH6 and PMS2 (Wang Q et al. J Med Genet, 2020 07;57:487-499). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Two other alterations at this position (c.251-2A>G and c.251-2A>C) have been reported as pathogenic in Lynch syndrome and CMMR-D cohorts (Senter L et al. Gastroenterology. 2008 Aug;135:419-28; Niessen RC et al. Genes Chromosomes Cancer. 2009 Apr;48:322-9). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Labcorp Genetics (formerly Invitae), Labcorp RCV000524468 SCV000261085 pathogenic Hereditary nonpolyposis colorectal neoplasms 2024-01-18 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 3 of the PMS2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs587779340, gnomAD 0.0009%). Disruption of this splice site has been observed in individuals with constitutional mismatch repair deficiency syndrome and/or Lynch syndrome (PMID: 18602922, 21376568, 25980754). ClinVar contains an entry for this variant (Variation ID: 183893). Studies have shown that disruption of this splice site results in skipping of exon 4 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.
University of Washington Department of Laboratory Medicine, University of Washington RCV000205731 SCV000266117 likely pathogenic Lynch syndrome 2015-11-20 criteria provided, single submitter clinical testing
GeneDx RCV000216802 SCV000279538 pathogenic not provided 2022-06-10 criteria provided, single submitter clinical testing Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with a personal or family history consistent with pathogenic variants in this gene (Yurgelun 2015, Wang 2020); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25980754, 27779110, 26845104, 29625052, 31992580, 31447099, 32719484, 18602922)
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000515494 SCV000611600 pathogenic Lynch syndrome 4 2017-09-14 criteria provided, single submitter research
Counsyl RCV000515494 SCV000677814 likely pathogenic Lynch syndrome 4 2017-02-16 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000763591 SCV000894430 pathogenic Mismatch repair cancer syndrome 1; Lynch syndrome 4 2018-10-31 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001255210 SCV000920018 pathogenic Hereditary nonpolyposis colon cancer 2020-06-22 criteria provided, single submitter clinical testing Variant summary: PMS2 c.251-2A>T is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.1e-06 in 244282 control chromosomes (gnomAD). c.251-2A>T has been reported in the literature in individuals affected with Hereditary Nonpolyposis Colorectal Cancer (e.g. Yurgelun_2015). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight ClinVar submitters (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000205731 SCV000967786 pathogenic Lynch syndrome 2018-03-09 criteria provided, single submitter clinical testing The c.251-2A>T variant in PMS2 has been reported in one individual with suspecte d Lynch syndrome (Yurgelun 2015) and has also been reported by other clinical la boratories in ClinVar (Variation ID# 183893). Additionally, two other variants a t this position (c.251-2A>C, c.251A>G) have been reported in individuals with PM S2-related cancers (Herkert 2011, Senter 2008), one of which has also been class ified as pathogenic on September 5, 2013 by the ClinGen-approved InSiGHT expert panel (ClinVar SCV000108354.2). The c.251A>T variant has also been identified in 1/108456 European chromosomes by the Genome Aggregation Database (gnomAD, http: //gnomad.broadinstitute.org; dbSNP rs587779340). This frequency is low enough to be consistent with the frequency of Lynch syndrome in the general population. T his variant occurs in the invariant region (+/- 1,2) of the splice consensus seq uence and is predicted to cause altered splicing leading to an abnormal or absen t protein. Heterozygous loss of function of the PMS2 gene is an established dise ase mechanism in individuals with Lynch syndrome. In summary, this variant meets criteria to be classified as pathogenic for Lynch syndrome in an autosomal domi nant manner based upon predicted impact to the protein, very low frequency in th e general population and the presence of a different pathogenic variant at the s ame position. ACMG/AMP criteria applied (Richards 2015): PVS1, PM5, PM2.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000216802 SCV002047295 pathogenic not provided 2020-11-16 criteria provided, single submitter clinical testing This variant is located in a canonical splice-acceptor site and interferes with normal PMS2 mRNA splicing. The variant has been reported in individuals with suspected Lynch syndrome in the published literature (PMID: 31992580 (2020), 25980754 (2015)). Based on the available information, this variant is classified as pathogenic.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV003149993 SCV003837739 pathogenic Breast and/or ovarian cancer 2021-07-28 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV000515494 SCV004019796 likely pathogenic Lynch syndrome 4 2023-04-04 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.
Baylor Genetics RCV000515494 SCV004207813 pathogenic Lynch syndrome 4 2023-06-07 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000162757 SCV004359698 pathogenic Hereditary cancer-predisposing syndrome 2023-01-31 criteria provided, single submitter clinical testing This variant causes an A to T nucleotide substitution at the -2 position of intron 3 of the PMS2 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. This variant has been reported in individuals suspected of having Lynch syndrome or colorectal cancer with clinical features of Lynch syndrome (PMID: 25980754, 31992580), in individuals with ovarian cancer (PMID: 33881185) and oligodendroglioma (PMID: 35982947). This variant has been identified in 1/244282 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same splice donor site (c..251-2A>G, c.251-2A>C) are known to be disease-causing (ClinVar variation ID: 91345, 233781). Loss of PMS2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
All of Us Research Program, National Institutes of Health RCV000205731 SCV004814295 pathogenic Lynch syndrome 2024-01-22 criteria provided, single submitter clinical testing This variant causes an A to T nucleotide substitution at the -2 position of intron 3 of the PMS2 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. This variant has been reported in individuals suspected of having Lynch syndrome or colorectal cancer with clinical features of Lynch syndrome (PMID: 25980754, 31992580), in individuals with ovarian cancer (PMID: 33881185) and oligodendroglioma (PMID: 35982947). This variant has been identified in 1/244282 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same splice donor site, c..251-2A>G and c.251-2A>C, are known to be disease-causing (ClinVar variation ID: 91345, 233781). Loss of PMS2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic RCV000216802 SCV000691979 pathogenic not provided no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000216802 SCV001552740 pathogenic not provided no assertion criteria provided clinical testing The PMS2 c.251-2A>T variant was identified in 1 of 2520 proband chromosomes (frequency: 0.0004) from individuals or families with Lynch syndrome (Yurgelun 2015). The variant was also identified in dbSNP (ID: rs587779340) as "With Likely pathogenic, Pathogenic allele", ClinVar (classified as pathogenic by Ambry genetics, Invitae, GeneDx and two clinical laboratories; as likely benign by two submitters), and in Insight Hereditary Tumors Database (3x ). The variant was not identified in GeneInsight-COGR, Cosmic, or Mismatch Repair Genes Variant, databases. The variant was identified in control databases in 1 of 239164 chromosomes at a frequency of 0.000004 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the European population in 1 of 108456 chromosomes (freq: 0.000009), while the variant was not observed in the African, Other, Latino, Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. The c.251-2A>T variant is predicted to cause abnormal splicing because the nucleotide substitution occurs in the invariant region of the splice consensus sequence. In addition, 4 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing. A different variant affecting this nucleotide (c.251-2A>G) classified as pathogenic, has been found in Lynch syndrome patients as biallelic PMS2 gene mutation (Herkert 2011, Senter 2008). In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
PreventionGenetics, part of Exact Sciences RCV004742289 SCV005361571 pathogenic PMS2-related disorder 2024-06-07 no assertion criteria provided clinical testing The PMS2 c.251-2A>T variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in multiple individuals with Lynch syndrome or various cancers, including lung squamous cell carcinoma and oligodendroglioma (see for example, Table A2, Espenschied et al. 2017. PubMed ID: 28514183; Table S2, Huang et al. 2018. PubMed ID: 29625052; Figure 3, Merchant et al. 2022. PubMed ID: 35982947). This variant is reported in 0.00090% of alleles in individuals of European (non-Finnish) descent in gnomAD and it is classified as pathogenic and likely pathogenic by other institutions in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/183893/). Variants that disrupt the consensus splice acceptor site in PMS2 are expected to be pathogenic. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.